Drugs / LY-N001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT07685444 | Jul 2026 → Jul 2028 expected | Parkinson disease | Lingyi Biotech Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LY-N001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07685444 ↗ |
| Route | Other | “LY-N001 Injection shall be administered as a single intracerebroventricular (ICV) injection, with one administration only” NCT07685444 ↗ |